Table 3 Impact of peer support on virologic failure at months 6, 12, 18 and 24 (n = 640)
Months | Intervention group (n = 332) | Control group (n = 308) | RR | 95% CI | P-Value** | ||
|---|---|---|---|---|---|---|---|
Virologic failure risk (95% CI) | Virologic failure risk (95% CI) | Virologic failure risk (95% CI) | Cumulative virologic failure risk (95% CI) | ||||
6 m | 11 (3.3%, 1.4–5.2%) | 11 (3.3%, 1.4–5.2%) | 11 (3.5%, 1.5–5.6%) | 11 (3.5%, 1.5–5.6%) | 0.9 | 0.4 < RR < 2.1 | 0.86 |
12 m | 6 (1.8%, 0.3–3.2%) | 17 (5.1%, 2.7–7.5%) | 9 (2.9%, 1–4.8%) | 20 (6.5%, 3.7–9.3) | 0.6 | 0.2 < RR < 1.7 | 0.35 |
18 m | 4 (1.2%, 0.1–2.3%) | 21 (6.3%, 3.6–9%) | 1 (0.3%, 0–1%) | 21 (6.8%, 3.9–9.7%) | 3.7 | 0.4 < RR < 33 | 0.21 |
24 m | 2 (0.6%, 0–1.4%) | 23 (6.9%, 4.1–9.7%) | 2 (0.6%, 0–1.5%) | 23 (7.5%, 4.4–10.5%) | 0.9 | 0.1 < RR < 6.5 | 0.94 |